Introduction
============

The occurrence of cancer continues to increase, and cancer constitutes an enormous burden on society [@B1]. The current strategies to cancer management have significantly improved some types of cancer patients\' overall survival (OS). However, the outcome still remains undesirable. The identification of molecular biomarkers which can use to evaluate potential high-risky cancer patients was therefore of great clinical value. Currently, with the advancements in transcriptome profiling, the number of long noncoding RNAs (lncRNAs) with limited or no protein-coding capacity found in the human genome exceeded ten thousand, but only a tiny fraction of lncRNAs have been functionally characterized [@B2],[@B3]. Growing evidence has revealed that lncRNAs may play a role in the development and progression of cancer [@B4]-[@B6]. And, some of them could become a new class of cancer biomarkers implicated in diagnosis, prognostication and therapeutic targets, such as HOTAIR and MALAT-1 [@B7]-[@B9]. Therefore, more specific lncRNAs with predictive and prognostic value in management of cancer need to be further teased out.

Colon Cancer-Associated Transcript 2 (CCAT2), a lncRNA that spans the highly conserved 8q24 region harboring the rs6983267 SNP, first discovered by ling *et al.* [@B10]. The G allele of the rs6983267 SNP was associated with greater predisposition to colorectal cancer (CRC) than the T allele [@B11], and the expression and function of CCAT2 were affected by rs6983267 alleles [@B10]. CCAT2 could induce chromosomal instability and metastases, partly through *MYC* and Wnt signaling pathway [@B10]. Recently, CCAT2 was found to reprogram energy metabolism in an allele-specific manner by interacting with the Cleavage Factor I (CFIm) complex to regulate the alternative splicing of glutaminase [@B12]. Those results suggest that abnormal expression of CCAT2 may contribute to a potential high malignancy degree of cancer.

Abnormal expression of CCAT2 has been reported in various kinds of cancer, including the microsatellite stable CRC, breast cancer, gastric cancer (GC), small cell lung cancer (SCLC), cervical squamous cell cancer (CSCC), ovarian cancer, bladder cancer, oral squamous cell carcinoma (OSCC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), prostate cancer, and hepatocellular carcinoma (HCC) [@B10], [@B13]-[@B24]. High expression of CCAT2 has been reported associated with metastasis and prognosis in different types of cancer, which indicated the diagnostic or prognostic value of CCAT2 for cancer [@B13]-[@B16], [@B20], [@B22], [@B23]. However, the results from each study were insufficient and not completely consistent in the correlation between CCAT2 and the clinical metastatic factors (as lymph node metastasis (LNM) and distance metastasis (DM)) or prognostic factors (like OS and progression free survival (PFS)). This meta-analysis was conducted to identify the relationship of CCAT2 with cancer patients\' clinical outcome, to further validate whether CCAT2 could serve as a feasible biomarker for metastasis and prognosis.

Methods
=======

Literature search strategies
----------------------------

An exhaustive search was performed in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, VIP database and Wanfang database. The last update of searching time was November 9, 2016. There was no language restriction. The keywords for the search were as follows: "long non-coding RNA CCAT2" or "lncRNA CCAT2" or "CCAT2" or "colon cancer-associated transcript 2" and cancer or carcinoma or tumor or tumour or neoplasms. Besides, the reference lists are manually viewed to get potentially eligible papers and authors contacted for further information where necessary.

Inclusion and exclusion criteria
--------------------------------

The criteria for inclusion was as follows: 1) articles evaluating the role of CCAT2 in the development of any type of human cancer, 2) the expression levels of CCAT2 in primary tumor tissue were detected, and 3) patients were grouped based on the expression levels of CCAT2, 4) reporting of clinical characteristics or outcomes, including LNM or DM or OS or PFS, 5) having sufficient data for calculating the odds ratios (OR) or hazard ratios (HR) and corresponding 95 % confidence intervals (CI).Exclusion criteria were the following: 1) nonhuman research, reviews, editorials, expert opinions, letters, and case reports, 2) studies without sufficient data, 3) duplicate publications.

Data extraction and quality assessment
--------------------------------------

The information was independently extracted and investigated by TJ and HYC from each included studies following the criteria for inclusion and exclusion stated above. A consensus was created by the third investigator (CYX) if there were disagreements. All eligible studies were assessed to be of high quality by using the Newcastle-Ottawa Scale (NOS). For each eligible study, the following information was collected: first author, year of publication, country, tumor type, total number of patients, number of high CCAT2 expression group and low CCAT2 expression group, number of patients with LNM and DM, detection method of CCAT2 expression levels, HRs, and corresponding 95% CIs for OS or PFS. All articles included were assessed the quality with the NOS by two investigators (TJ and HYC) independently.

Statistical methods
-------------------

All the statistical analyses in this meta-analysis were conducted by using Review Manager version software 5.3.5 (Nordic Cochrane Center) and Stata statistical software version 13.0 (StataCorp, USA). Data of HRs were directly extracted from the eligible studies. If the articles only provided survival curves without offering HR, calculation method introduced by Tierney *et al.* [@B25] and Parmar *et al.* [@B26] was applied to extract HR with 95%CI using Engauge Digitizer (version 4.1).

The heterogeneity among studies was evaluated by using the Q test (with a significance level of *P*\< 0.10) and I^2^statistics [@B27]. A value of I^2^ of 0%-30%, 31%-50%, 51%-75%, and 75%-100% each represents an insignificant, low, moderate, and considerable heterogeneity, respectively [@B27]. A model of random-effect was employed to analyze the data independent of heterogeneity, which renders more precise and authentic results [@B28]. Begg\'s test was used to assess the potential publication bias. A two-tailed *P*values \< 0.05 was considered statistically significant.

Results
=======

Characteristics of eligible studies
-----------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, a total of 63 published articles were identified from the first attempt to search by using the keywords, of which 23 duplicates were excluded. After screening the title and abstract carefully, 28 articles were excluded. After further inspection of the full articles, 5 articles were excluded, including 3 not relevant to LNM, DM or prognosis, 2 without sufficient data to achieve HR with 95 % CI. Finally, according to the criteria for selection, a total of 8 studies were eligible in this meta-analysis.

Table [1](#T1){ref-type="table"} showed the main characteristics of the included publications. A total of 8 studies involving 867 cancer patients were included. The mean of sample size was 108.4 (range from 48 to 227). Among the eight studies, CCAT2 was tested in 8 types of cancers including prostate cancer, SCLC, ovarian cancer, GC, CSCC, bladder cancer, breast cancer and ESCC. Quantitative real-time PCR (qRT-PCR) was used in all studies to detect CCAT2 expression, of which 7 studies chose GAPDH as a reference gene. In all of the studies, the patients were divided into two groups: high and low expression of CCAT2.

Meta-analysis results
---------------------

### Association between CCAT2 and LNM

In the eight eligible studies, six studies reported the LNM of 691 patients based on different CCAT2 expression levels [@B14], [@B15], [@B17], [@B20], [@B22], [@B23]. Four studies demonstrated a statistically significant relationship between high CCAT2 expression and more LNM [@B14], [@B15], [@B20], [@B22]; the remaining 2 studies did not indicate any association [@B17], [@B23]. The OR (the value of high CCAT2 expression group versus low CCAT2 expression group) was 3.09 (95%CI 1.53-6.26, *P* = 0.002) with a moderate heterogeneity (*I^2^* = 70.0%, Q = 16.76, *P* ~bias~ = 0.005) in a pooled analysis of all 6 studies.

### Association between CCAT2 and DM

Among the eight eligible studies, only 4 studies reported the DM of patients, including 402 patients [@B14], [@B16], [@B20], [@B23]. The result of meta-analysis showed a pooled OR which was 7.70 (95% CI: 3.26 - 18.17, *P*\< 0.01) and low heterogeneity (*I^2^* = 43.0%, *P* ~bias~ = 0.15) (Figure [3](#F3){ref-type="fig"}). Obviously, patients with high CCAT2 expression were more likely to DM.

### Association between CCAT2 and OS

Seven studies including 819 patients were assessed for the correlation between CCAT2 and OS (Table [2](#T2){ref-type="table"}) [@B13]-[@B16],[@B20],[@B22],[@B23]. High CCAT2 expression was significantly correlated with poor prognosis (HR 2.19; 95% CI: 1.70-2.82; *P*\<0.01) with a low heterogeneity (*I^2^* = 28%; *P* ~bias~ = 0.21), compared with low CCAT2 expression in a pooled analysis of all seven studies (Figure [4](#F4){ref-type="fig"}).

### Association between CCAT2 and PFS

As shown in Table [2](#T2){ref-type="table"}, three studies reported the PFS of patients [@B15], [@B20], [@B23]. The result indicated that higher expression of CCAT2 might predict poor PFS in various cancers (HR 2.59; 95% CI: 1.78-3.76; *P*\<0.01), with a low heterogeneity (*I^2^* = 0%; *P* ~bias~ = 0.75) (Figure [5](#F5){ref-type="fig"}).

Subgroup analysis
-----------------

Subgroup analyses across several different variables were further performed to investigate the heterogeneity of the studies for meta-analysis of CCAT2 and LNM. The LNM related data was stratified into subgroups based on sample size, tumor type, reference control and RNA extraction. The assessment results in each subgroup are also shown in Table [3](#T3){ref-type="table"}. Subgroup analysis by sample size explored that high CCAT2 expression status was related to high LNM numbers in big sample size group (n ≥ 100, OR 3.77, 95%CI 1.57 - 9.05, *P* \< 0.01), but not in small size group(n \< 100, OR 1.91, 95%CI 0.38 - 9.57, *P* = 0.43). However, when conducting subgroup analyses on tumor type, we found no significant correlation between high CCAT2 expression and LNM among the studies in Digestive system or Urinary system. According to the results presented in Table [3](#T3){ref-type="table"}, when divided by reference control, the subgroup analysis showed that in GAPDH group, up-regulated CCAT2 was associated with more LNM (OR 3.66, 95%CI 1.67-8.03, *P*\< 0.01). As for different RNA extraction method for CCAT2, the relationship between CCAT2 expression and tumor LNM was significant in TRIzol group (OR 2.88, 95%CI 1.01-8.22, *P* \< 0.05), but not in others group (OR 3.22, 95%CI 0.94-11.01, *P* = 0.06).

Sensitivity analysis
--------------------

Multiple sensitivity analyses were performed to evaluate whether individual study influenced pooled ORs or HR by excluding one study by turns. It was found that none of the exclusions of a specific study would change the magnitude or direction of the summary effect for the correlation between CCAT2 expression and LNM or OS, which further confirmed the validity of the results (Figure [6](#F6){ref-type="fig"}/7). The publication bias and sensitivity analysis for DM and PFS were not assessed due to the limited number of studies involved and no severe heterogeneity among studies.

Publication bias
----------------

In our meta‑analysis, Begg\'s tests were introduced to examine potential publication bias. No evidence supporting publication bias was found in analysis between CCAT2 and LNM (*P* = 1.00) (Figure [8](#F8){ref-type="fig"}) and analysis between CCAT2 and OS (*P* = 0.133) (Figure [9](#F9){ref-type="fig"}). The publication bias, however, cannot be determined on account of the limited number of studies involved in the current meta-analysis.

Discussion
==========

Evidence from growing publications showed that lncRNAs, similar to protein-coding genes, have oncogenic or tumor-suppressing effects, implicating in various tumorigenesis processes including proliferation, apoptosis and invasion. More and more functional lncRNAs were found to have potential value on predicting disease progression [@B4]-[@B6], [@B8], [@B29]-[@B31]. CCAT2, a functional lncRNA, first named in 2013, could enhance invasion and metastasis and involve in migration and chemo-resistance in a SNP-independent manner [@B10], [@B32]. Recently, CCAT2 was discovered to regulate cancer metabolism in an allele-specific manner by fine-tuning the alternative splicing of glutaminase through interaction with the CFIm complex [@B12]. The crucial action of CCAT2 inside the molecular carcinogenesis indicated its potential value for diagnosis or prognosis. However, a persuasive support of the CCAT2 in clinical practice is still unavailable, partially due to the uncertainty of the relationship between CCAT2 and metastasis or prognosis implication. Several investigations established a statistically significant relationship between high CCAT2 expression and metastasis (LNM or DM). Nevertheless, some researchers demonstrated an unfavorable impact of CCAT2 abnormality on clinical metastasis. A comprehensive study is therefore demanded.

In the present study, we systematically explored the correlation between CCAT2 and clinic pathological features and prognosis in cancer. Eight eligible studies were summarized quantitatively based on our inclusion and quality assessment criteria. The findings of the current study demonstrated that high CCAT expression was positively correlated with the increase in the risk of LNM and DM in cancer patients. Moreover, we identified that there was a statistical significant positive relationship between CCAT expression and short OS or PFS in cancer patients. In multiple sensitivity analyses, we did not detect any substantial difference in pooled estimates, and there was no excessive influence on the overall results in any individual study.

Among seven studies assessed for the correlation between CCAT2 and OS, six studies used multivariate survival analysis to calculate the HRs and 95% CIs for OS [@B14]-[@B16], [@B20], [@B22], [@B23], and in the included studies for PFS [@B15], [@B20], [@B23], all papers used multivariate survival analysis, suggesting that SPRY4-IT1 expression could probably serve as an independent predictor for OS and PFS. In the included studies from present study, only one study from Huang SY *et al.* [@B16], reported the association between increased CCAT2 expression and disease free survival (DFS) in ovarian cancer, thus meta-analysis was not performed for DFS.

Our meta-analysis provided evidence that CCAT2 expression was positively correlated with the clinical metastatic factors (LNM and DM) in patients with various cancer types. Only two studies reported no association between increased CCAT2 expression and LNM in prostate cancer and bladder cancer, respectively, which might be caused by the small size or the tumor type [@B17], [@B23]. The mechanism on regulatory activity of CCAT2 in cancer invasion and metastasis has been explored in several cancer types. In a study by Ling *et al.* [@B10], cell invasion and metastasis could be promoted by CCAT2 via the *MYC*-regulated miRNA-17-5p and miRNA-20a. Another study investigated on the function of CCAT2, revealing that CCAT2 might disturb metastasis by regulating EMT-related gene expression (N-cadherin, vimentin and E-cadherin) [@B23]. Recently, Redis *et al.* [@B12] reported that CCAT2 regulates the alternative splicing of GLS, resulting in the preferential expression of the more aggressive splice isoform, which promotes *in vivo* metastases and *in vitro* cell migration. These molecular mechanisms of CCAT2 involved cancer progression could elucidate why CCAT2 may serve as a potential biomarker for predicting the patient prognosis.

It is important to explore the sources of heterogeneity in a meta-analysis. In this study, there was insignificant or low heterogeneity among studies analyzing connection between CCAT2 expression and OS or PFS or DM. However, moderate heterogeneity was found during the analyzing correlation between CCAT2 and LNM (*I^2^*=70%). Subgroup analyses were conducted according to the majors attributes of primary studies. In present study, different measures, such as reference controls and RNA extractions, were used to extract CCAT2 in different studies. All these variables may influence the heterogeneity. Subgroup analysis showed that reference controls did not change the overall result, but that the sample size, and RNA extractions did. The results showed that big sample size had higher accuracy than small sample size for predicting LNM.

There were also several potential limitations in our study. Firstly, a few clinical studies have focused on CCAT2 at present, and the sample size is therefore small. The data in our analyses were relatively insufficient, which may cause a small-study effect. Secondly, all eligible studies were from China in Asian area, with no Caucasian or African population involved, so the results warranted to be further validated in other population. Thirdly, the cut-off value of high and low CCAT2 expression varied in different studies. It was difficult to reach a same value. Fourthly, our meta-analysis may overestimate the significance of CCAT2 to some extent because studies with null results tend not to be published, even though no conclusive evidence supporting publication bias was observed via visual examination of funnel plot and the Begg test. Fifthly, other parameters that might have a great effect on survival, such as postsurgical treatment and biological types of carcinoma, were not explored, which may result in some heterogeneity.

In conclusion, the expression of CCAT2 was significantly associated with metastasis (LNM, DM) and prognosis (OS, PFS) in different types of cancer. The higher expression of CCAT2, the higher probability of occurrence of LNM and DM patients might suffer with. Meanwhile, shorter OS and PFS may be observed in the patients with high CCAT2 expression. Thus, CCAT2 might be a novel predictive factor for estimating the clinical outcome in different types of cancer. However, further large-scale studies are needed to confirm its value.
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###### 

Characteristics of studies in this meta-analysis

  Author     Year   Country   Tumor type   Sample size   CCAT2 expression   CCAT2 assay                        
  ---------- ------ --------- ------------ ------------- ------------------ ------------- ---- ----- ---- ---- ---------
  Zheng JF   2016   China     PC           96            59                 10            32   37    5    8    RT-qPCR
  Chen SF    2016   China     SCLC         112           56                 45            14   56    22   0    RT-qPCR
  Huang SY   2016   China     OC           109           55                 NA            36   54    NA   6    RT-qPCR
  Wang CY    2015   China     GC           85            44                 28            11   41    8    3    RT-qPCR
  Chen X     2015   China     CSCC         123           62                 34            NA   61    11   NA   RT-qPCR
  Li JF      2016   China     BC^1^        48            28                 1             NA   20    2    NA   RT-qPCR
  Zhang XL   2015   China     ESCC         227           114                65            NA   113   48   NA   RT-qPCR
  Cai Y      2015   China     BC^2^        67            25                 NA            NA   42    NA   NA   RT-qPCR

PC prostate cancer, SCLC small cell lung cancer, OC Ovarian cancer, GC gastric cancer, CSCC cervical squamous cell cancer, BC^1^ bladder cancer, ESCC esophageal squamous cell carcinoma, BC^2^ breast cancer, qRT-PCR quantitative real-time PCR, LNM lymph node metastasis, DM distant metastasis, NA not available.

###### 

Survival data of the eligible studies in this meta-analysis

  Author     Year   Tumor type   Sample size   Survival analysis   Multivariate analysis   HR statistic   Hazard ratios(95% CI)   RNA extraction        Reference control                                                 
  ---------- ------ ------------ ------------- ------------------- ----------------------- -------------- ----------------------- --------------------- --------------------- ------------------------------------------- -------
  Zheng JF   2016   PC           96            Yes                 Yes                     Yes            Data in paper           2.292 (1.370-3.528)   2.276 (1.199-2.768)   TRIzol(Invitrogen)                          GAPDH
  Chen SF    2016   SCLC         112           Yes                 NA                      Yes            Data in paper           2.034 (1.216-3.402)   NA                    RNAiso Plus (TAKARA)                        GAPDH
  Huang SY   2016   OC           109           Yes                 NA                      Yes            Data in paper           2.938 (1.526-5.873)   NA                    TRIzol(Invitrogen)                          GAPDH
  Wang CY    2015   GC           85            Yes                 Yes                     Yes            Data in paper           2.405 (1.194-5.417)   2.315 (1.097-5.283)   TRIzol(Invitrogen)                          GAPDH
  Chen X     2015   CSCC         123           Yes                 Yes                     Yes            Data in paper           2.813 (1.504-6.172)   3.072 (1.716-8.174)   TRIzol(Invitrogen)                          GAPDH
  Zhang XL   2015   ESCC         227           Yes                 NA                      Yes            Data in paper           1.432 (1.005-2.041)   NA                    Total Nucleic Acid Isolation Kit (Ambion)   RNU6B
  Cai Y      2015   BC^1^        67            Yes                 NA                      No             Survival curve          3.87 ( 1.57-9.50 )    NA                    TRIzol(Thermo)                              GAPDH

OS Overall survival, PFS progression free survival, PC prostate cancer, SCLC small cell lung cancer, OC Ovarian cancer, GC gastric cancer, CSCC cervical squamous cell cancer, BC^1^ breast cancer, ESCC esophageal squamous cell carcinoma, Y Yes, NA not available, 95%CI 95% confidence interval.

###### 

Subgroup analysis of the role of CCAT2 in LNM in different types of cancer

  Subgroup            No. of studies   No. of patients   Test of Relationship            Test of Heterogeneity                   
  ------------------- ---------------- ----------------- ---------------------- -------- ----------------------- ------- ------- ----
  Overall             6                691               3.09 (1.53-6.26)       \<0.01                           15.68   0.005   70
  Sample size                                                                                                                    
  \< 100              3                229               1.91 (0.38-9.57)       0.43                             8.03    0.02    75
  ≥ 100               3                462               3.77 (1.57-9.05)       \<0.01                           8.72    0.01    77
  Tumor type                                                                                                                     
  Digestive system    2                312               3.37 (0.87-13.11)      0.08                             5.95    0.01    83
  Urinary system      2                144               1.02 (0.36-2.92)       0.97                             0.96    0.33    0
  Others              2                235               5.89 (3.26-10.64)      \<0.01                           0.05    0.82    0
  Reference control                                                                                                              
  GAPDH               5                464               3.66 (1.67-8.03)       \<0.01                           10.35   0.03    61
  RNU6B               1                227               1.80 (1.06-3.04)       0.03                             \-      \-      \-
  RNA extraction                                                                                                                 
  TRIzol              4                352               2.88 (1.01-8.22)       \<0.05                           9.39    0.02    68
  Others              2                339               3.22 (0.94-11.01)      0.06                             6.09    0.01    84

LNM, lymph node metastasis; OR, odds ratio; 95%CI, 95% confidence interval.
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